Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trialRupert Bartsch, Matthias Preusser, Anna S. Berghoff et al.|Nature Medicine|2022Cited by 395
Activity of T-DM1 in Her2-positive breast cancer brain metastasesRupert Bartsch, Matthias Preusser, Christoph Zielinski et al.|Clinical & Experimental Metastasis|2015Cited by 122
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastasesRupert Bartsch, Matthias Preusser, Anna S. Berghoff et al.|Neuro-Oncology|2024Cited by 60
Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain MetastasesElisabeth Bergen, Rupert Bartsch, Anna S. Berghoff et al.|Clinical Cancer Research|2019Cited by 46
Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumabElisabeth Bergen, Rupert Bartsch, Amelie Binter et al.|Therapeutic Advances in Medical Oncology|2021Cited by 32